Login to Your Account



Toxicity Issues Halt PBT1 Program In Alzheimer's; Prana's Stock Falls

By Jennifer Boggs


Wednesday, April 13, 2005
Prana Biotechnology Ltd.'s dreams of becoming a late-stage drug development company in 2005 suffered a blow Monday with the company's decision to cancel an upcoming Phase II/III trial of PBT1, a disease-modifying compound for Alzheimer's disease, due to manufacturing toxicity issues. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription